Submitted by Anonymous (not verified) on 24 November 2025 - 13:20
Human medicines European public assessment report (EPAR): Crysvita, burosumab, Date of authorisation: 19/02/2018, Revision: 16, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Crysvita, burosumab, Date of authorisation: 19/02/2018, Revision: 16, Status: Authorised